Company intelligence / Profile preview

DeuteRx

Ownership: Private
Development stage: Preclinical

Overview

DeuteRx has developed multiple drug candidates using their DECS platform to improve racemic drugs. Several programs appear to have been discontinued, with NTY-184 for Major Depressive Disorder currently in preclinical stage.

Therapeutic areas: GastroenterologyPsychiatryHematologyOncologyRare DiseasesNeurology
Modalities: Small moleculesdeuterated compounds
Industry: Biotech

Drug pipeline

1 asset

SP-3164

Pre-clinical

Indications: Hematological cancers, Solid tumors

Partnerships

CelgenePoxel SASalarius Pharmaceuticals, Inc.

Beyond the preview

Go deeper on DeuteRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeuteRx.

Explore the full profile